Abstract:A major clinical obstacle in cancer therapy is the development of resistance to chemotherapeutic agents. Intrinsic or acquired drug resistance occurs frequently in most cancers. Many strategies are being developed towards overcoming such drug resistance. Among them, application of nanotechnology has shown promise in the development of novel drug delivery approaches to overcome drug resistance by targeting tumor tissue, tumor cells, or compartments within tumor cells. We synthesized a targeted nanoparticle composed of heparin-folate-paclitaxel (HFT) conjugates and loaded with paclitaxel in its hydrophobic core (HFT-T). In vitro cytotoxicity of the HFT-T nanoparticle was assessed in a resistant human squamous cancer cell line KB-8-5 (10-fold more resistant to paclitaxel than the parental sensitive cell line KB-3-1). The targeted nanoparticle HFT-T was more effective in inhibiting cell growth when compared with the non-targeted nanoparticle (HT-T). To test the in vivo efficacy of HFT-T particles, nude mice bearing subcutaneous human KB-8-5 tumors were randomly divided into four groups (n=8 per group), and treated with HFT-T, free paclitaxel, HT-T or PBS (control). The drugs (at a dose of 40 mg/kg paclitaxel equivalent) were administrated via tail vein every four days for 3 weeks (4 injections in total). At the end of the experiment, the HFT-T-treated group showed the smallest tumor sizes (average tumor volume of 785.5±104.1 mm 3 ) when compared with other treated mice or controls (average tumor volumes in free paclitaxel, HT-T-treated, and control groups were 1422.9 ± 216.1 mm 3 , 1301.2 ± 213.9 mm 3 , 2061.7± 416.1, respectively). Compared with free paclitaxel and non-targeted nanoparticle HT-T treated groups, HFT-T treatment significantly reduced tumor size (paclitaxel vs. HFT-T p=0.0155, HT-T vs. HFT-T p=0.0381). Also, compared with the control group, only HFT-T treatment significantly reduced tumor size (p=0.0075). Furthermore, the effect of HFT-T on microtubule organization and apoptosis in tumor will be studied. In conclusion, this study provides a novel strategy using a targeted nanoparticle as a drug delivery system to minimize drug resistance in human cancers. (Supported by NCI P50 CA128613 and U54CA119338-04) Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3667.

Folate Functionalized Ph-Sensitive Nanoparticulate System to Decrease the Toxicity and Enhance the Anti-Cancer Activity of Pirarubicin for Lymphoma Therapy Via Downregulation of H3K18la and H3K9la

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

Characterization and Pharmacokinetics of a Novel Pirarubicin Liposome Powder

Enhancing Targeted Therapy in Hepatocellular Carcinoma Through a Ph-Responsive Delivery System: Folic Acid-Modified Polydopamine-Paclitaxel-Loaded Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Nanoparticles.

Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin.

Blended Nanoparticle System Based on Miscible Structurally Similar Polymers: A Safe, Simple, Targeted, and Surprisingly High Efficiency Vehicle for Cancer Therapy

Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.

Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.

Abstract #3667: A novel folate receptor-targeted nanoparticle minimizes drug resistance in a human cancer model

Preliminary Study on Pharmacokinetics and Antitumor Pharmacodynamics of Folic Acid Modified Crebanine Polyethyleneglycol-Polylactic Acid Hydroxyacetic Acid Copolymer Nanoparticles

Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents.

Development of Novel Lignin-Based Targeted Polymeric Nanoparticle Platform for Efficient Delivery of Anticancer Drugs.

Folic Acid-Targeted Mixed Pluronic Micelles for Delivery of Triptolide

Metabonomic Study on the Cumulative Cardiotoxicity of a Pirarubicin Liposome Powder

A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin's lymphoma

PLGA-PLL-PEG-Tf-based Targeted Nanoparticles Drug Delivery System Enhance Antitumor Efficacy Via Intrinsic Apoptosis Pathway

Folate-modified Erythrocyte Membrane Nanoparticles Loaded with Fe3O4 and Artemisinin Enhance Ferroptosis of Tumors by Low-Intensity Focused Ultrasound

Co-delivery of Doxorubicin and Shrna of Beclin1 by Folate Receptor Targeted Pullulan-Based Multifunctional Nanomicelles for Combinational Cancer Therapy

Functionalized PAMAM-Based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.

Enhanced antitumor efficacy of folate modified amphiphilic nanoparticles through co-delivery of chemotherapeutic drugs and genes.

Folate-conjugated and Ph-Responsive Polymeric Micelles for Target-Cell-specific Anticancer Drug Delivery.